{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004433","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.964667+00:00","generated_at":"2026-06-13T10:32:35.868775+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Arbutus appoints Karen Sims as CMO, Christopher Naftzger as GC and CCO","bullets":["Dr. Karen Sims promoted from VP Clinical Development to Chief Medical Officer, effective immediately.","Christopher Naftzger appointed General Counsel and Chief Compliance Officer; Dr. Elizabeth Howard remains advisor on patent litigation.","Naftzger granted inducement option for 500,000 common shares at July 10, 2023 closing price, vesting over 4 years.","Sims has 12+ years experience, previously at Bristol-Myers Squibb; Naftzger has 25+ years legal experience, most recently at Nabriva Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004433","json":"https://secwatch.observer/filing/0001171843-23-004433.json","markdown":"https://secwatch.observer/filing/0001171843-23-004433.md","text":"https://secwatch.observer/filing/0001171843-23-004433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004433/0001171843-23-004433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004433/f8k_070723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:32:35.868775+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}